In the volatile biotech industry, companies can see their shares soar over relatively short periods on strong clinical progress for exciting pipeline candidates.That’s precisely what could happen to Exelixis (NASDAQ: EXEL) and Summit Therapeutics (NASDAQ: SMMT) this year. And the even better news is that there are reasons to consider holding onto these drugmakers’ shares even beyond the next 12 months. Let’s find out more.Image source: Getty Images.Continue readinghttps://www.fool.com/investing/2026/01/31/2-stocks-that-could-soar-this-year/
I’ve been advising wealthy family offices on real estate for decades. This market requires another look at your 100-year plan
https://finance.yahoo.com/news/ve-advising-wealthy-family-offices-120000971.html